Key result
Anthracycline-induced cardiotoxicity limits clinical utility and drives development of liposomal and nanoparticle formulations.
Anthracyclines are a clinically important class of antineoplastic agents whose use is limited by cumulative dose-dependent cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Clinicians should monitor cumulative anthracycline doses to limit cardiotoxicity; leaves open comparative outcomes of liposomal formulations in prospective trials.
Cheong et al. (2018) conducted a review in Cancer. Anthracyclines was evaluated. Anthracyclines are effective antineoplastic agents whose clinical utility is limited by cumulative dose-dependent cardiotoxicity, prompting the development of liposomal and nanoparticle formulations.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: